newsfilter
← Latest News
GlobeNewswire·

Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting

CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (("Qualigen" or the "Company, NASDAQ:QLGN) today announces that a poster featuring its early clinical experience with a novel